Please login to the form below

Yescarta

This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.

Gracell reports impressive data with one-day CAR-T for leukaemia

3-4 week production process and Gilead suggests Yescarta takes 26-29 days to prepare. ... Yescarta and Kymriah have US list prices of $373, 000 and $475, 000 per procedure, respectively, and haven’t yet gathered much momentum in the market.

Latest news

Novartis’ CAR-T Kymriah scores SMC approval

Novartis’ CAR-T rival from Gilead, Yescarta, has a UK list price of nearly £300, 000 per patient.
Gilead strikes $5.1bn deal to bolster ties with Galapagos

CAR-T therapy for cancer Yescarta (axicabtagene ciloleucel) – acquired as part of its $12bn takeover of Kite – has been slow to build sales, bringing in $264m last year.
Europe urged to adapt faster to gene therapy challenges

s Yescarta, plus Spark/Roche’s gene therapy Luxturna, and most recently, the approval of Bluebird’s gene therapy Zynteglo.
Regeneron's bispecific for lymphoma works in CAR-T failures

At the moment, Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) are the CAR-Ts that have been approved to treat DLBCL, with pivotal trials showing that they can
MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

Results rival Kymriah and Yescarta - with less cost and complexity. ... and Gilead’s Yescarta (axicabtagene ciloleucel).

More from news
Approximately 8 fully matching, plus 42 partially matching documents found.

Latest Intelligence

25 Women Leaders in UK Healthcare (part 2)

It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to
Bluebird: on a mission to ‘recode’ the DNA of healthcare

years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug, Yescarta, is priced at $373, 000 (with European prices substantially lower than this).
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”

can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
Cell and gene therapy

Cell and gene therapies are currently expensive to manufacture. We do not believe that recently marketed products, with US prices ranging from $373, 000 for Yescarta to $850, 000 for Luxturna,
Drug launches to watch in 2019

1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

Training the next generation of biotech leaders

In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.